Navigation Links
NORD and DIA to Host Conference on Rare Diseases and Orphan Products
Date:9/14/2011

WASHINGTON, Sept. 14, 2011 /PRNewswire-USNewswire/ -- The National Organization for Rare Disorders (NORD) and the Drug Information Association (DIA) will host the U.S. Conference on Rare Diseases and Orphan Products in Washington, D.C. October 11-13.  Everyone with an interest in rare diseases or orphan products is invited.

(Logo: http://photos.prnewswire.com/prnh/20110719/DC37656LOGO-b)

"This conference will be truly unique in that it will draw together all the stakeholders from government, industry, academia and patient organizations," said Peter L. Saltonstall, president and CEO of NORD.  "Most of the nearly 7,000 rare diseases don't have FDA-approved treatments.  The purpose of this conference is to bring everyone together—government, industry, medical researchers, investors and patients—to examine the challenges and opportunities."

NORD is a nonprofit organization representing all Americans affected by rare diseases.  DIA is a nonprofit, global professional association of members involved in pharmaceutical and medical device discovery, development, and management.

Senior staff from the National Institutes of Health (NIH) and Food and Drug Administration (FDA) will speak at the conference, along with thought leaders from the pharmaceutical industry, medical researchers, and the investment community.  Speakers will include:

  • NIH Director Francis Collins, MD, PhD
  • Social Security Commissioner Michael Astrue
  • Christopher P. Austin, MD, PhD, Scientific Director, NIH Center for Translational Therapeutics
  • Janet Woodcock, MD, Director of FDA's Center for Drug Evaluation and Research
  • John K. Jenkins, MD, Director, Office of New Drugs, FDA Center for Drug Evaluation and Research
  • Suzanne L. Bruhn, PhD, Senior VP, Shire Human Genetic Therapies
  • Marc
    '/>"/>

SOURCE National Organization for Rare Disorder (NORD)
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
3. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
4. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
5. ViroPharma to Present at Three Upcoming Healthcare Conferences
6. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
7. Threshold Pharmaceuticals Announces Two Presentations on Glufosfamide at the 2007 European Cancer Conference (ECCO)
8. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
9. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
10. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Alfacell Corporation to Present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... YORK , July 29, 2015 /PRNewswire/ ... a new research report "Global Industry Insight: ... to 2020" with market overview, trends, DRO analysis, ... analysis, recent developments, competitive scenario and top ... http://photos.prnewswire.com/prnh/20150727/756778 ) Microfluidic devices  ...
(Date:7/29/2015)... LONDON , July 29, 2015 ... the Novartis transaction closed, CFO Simon Dingemans ... acquired businesses are performing in line with expectations. Ahead ... company,s commitment to sustainable innovation. The interview ... MerchantCantos produces in-depth interviews, documentaries and webcasts ...
(Date:7/29/2015)... , July 29, 2015  Cepheid (Nasdaq: ... an update to Xpert® Carba-R, with the addition ... OXA-232.  The on-demand, molecular test also detects and ... carbapenem resistance, namely KPC, NDM, VIM, IMP-1 and ... as CROs or Superbugs, are a growing and ...
Breaking Medicine Technology:Global Microfluidic Devices Market (Size of $1,886 Million in 2014) to Witness a CAGR of 23% During 2015 - 2020 2Global Microfluidic Devices Market (Size of $1,886 Million in 2014) to Witness a CAGR of 23% During 2015 - 2020 3Global Microfluidic Devices Market (Size of $1,886 Million in 2014) to Witness a CAGR of 23% During 2015 - 2020 4Global Microfluidic Devices Market (Size of $1,886 Million in 2014) to Witness a CAGR of 23% During 2015 - 2020 5'Superbug' Test Updated to Identify Newest Carbapenem-Resistant Organisms 2'Superbug' Test Updated to Identify Newest Carbapenem-Resistant Organisms 3'Superbug' Test Updated to Identify Newest Carbapenem-Resistant Organisms 4
... YORK, June 22, 2011 (Digital Experience!) -- iHealth ... personal healthcare products including the iHealth BP3 Blood Pressure ... announced that multiple national retail chains will now distribute ... Pressure Monitoring System is now available in all Apple ...
... Cempra Pharmaceuticals Inc. today announced that Prabhavathi ... the 2011 Wells Fargo Healthcare Conference at 1 p.m. ... provide an overview of the company,s two leading antibiotic ... infections and TAKSTA™ for the oral treatment of gram ...
Cached Medicine Technology:iHealth Lab's Blood Pressure Self-Monitoring System Gets Nationwide Distribution 2
(Date:7/29/2015)... , ... July 29, 2015 , ... It is unique ... “This is a tremendous model of care. One that is very hands on and ... executive director of Monarch Landing. “She’s bringing great passion and energy, as well as ...
(Date:7/29/2015)... ... July 29, 2015 , ... Stealth ... a Clinical Performance Study for the Invisiport at Wheaton Franciscan Healthcare in Milwaukee, ... options, offers a less invasive, patient-friendly alternative to traditional chest ports and peripherally ...
(Date:7/29/2015)... ... ... TransFlip is an all new dynamic transition pack for FCPX, containing flipping ... are easy to apply and modify for any skill-level user. TransFlip includes custom bounce ... kinetic flipping panel animations are just a few clicks away. , TransFlip contains over ...
(Date:7/29/2015)... ... July 29, 2015 , ... Zofran lawsuits around the ... Multidistrict Litigation (JPML), according to court documents.* Attorneys handling Zofran lawsuits ... Birth Defects Lawsuit Center. , GlaxoSmithKline, the global pharmaceutical conglomerate and defendant in ...
(Date:7/29/2015)... , ... July 29, 2015 , ... The New ... project, which will by the end will cost the 501(c) organization nearly $1 million, ... recent anti-ligature requirements. , “We took it down to the studs,” said Geraldine ...
Breaking Medicine News(10 mins):Health News:New Medical Director Readies To Take Reins at Monarch Landing 2Health News:New Medical Director Readies To Take Reins at Monarch Landing 3Health News:Stealth Therapeutics Inc. Enrolls First Patients in a Clinical Performance Study for the Invisiport Product Line 2Health News:Stealth Therapeutics Inc. Enrolls First Patients in a Clinical Performance Study for the Invisiport Product Line 3Health News:Pixel Film Studios Releases FCPX Transition TransFlip for FCPX 2Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 2Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 3Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 4Health News:The New Foundation AZ Renovates Residential Dorms for Youth in Crisis 2Health News:The New Foundation AZ Renovates Residential Dorms for Youth in Crisis 3
... takes a complete snapshot of adolescent cardiovascular health in the ... likely to die of heart disease at a younger age ... "We are all born with ideal cardiovascular health, but ... health in youth," said Donald Lloyd-Jones, M.D., chair and associate ...
... is the recipient of one of Canada,s top awards ... the mammalian immune system, Kubes will accept the 2011 ... Canadian Institutes of Health Research (CIHR) at a ceremony ... Kubes for winning this prestigious award," said the Honourable ...
... Like a gardener who stakes some plants and weeds ... synapses, while pruning out redundant or unneeded synapses. Researchers ... Zhang, Ph.D., have discovered a factor in synapse-building, also ... of each other. Mammals are born with functioning ...
... The American Academy of Orthopaedic Surgeons (AAOS) Board of ... practice guideline (CPG) on "The Treatment of Supracondylar Humerus ... surgeon, medical director of the Trauma Program at the ... chair of the AAOS Work Group responsible for this ...
... Aging Society and Services and Advocacy for GLBT ... acclaimed Public Policy & Aging Report (PPAR) on ... policy and research on LGBT older adults, and current and ... "Given the voluminous gerontological literature that has built up over ...
... less produce the finest foie gras that rich, buttery ... eaten as slices atop lightly toasted bread scientists are ... and Food Chemistry. Caroline Molette and colleagues explain ... gras, a traditional French dish, comes from its high fat ...
Cached Medicine News:Health News:Today's teens will die younger of heart disease 2Health News:Today's teens will die younger of heart disease 3Health News:University of Calgary researcher named Canada's Health Researcher of the Year 2Health News:University of Calgary researcher named Canada's Health Researcher of the Year 3Health News:Jackson Laboratory researchers uncover steps in synapse building, pruning 2Health News:AAOS issues new clinical practice guideline for treating common elbow fractures in children 2Health News:New report highlights LGBT older adults' needs, identifies policy opportunities 2
For the quantitative in vitro determination of Uric Acid in serum, plasma and urine...
For the quantitative in vitro determination of apolipoprotein A-1 (apo A-1) in serum and plasma. For use as an aid if assessing the risk of coronary artery disease....
For the quantitative in vitro determination of Urea in serum, plasma and urine....
The XTRI method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of triglycerides in serum and plasma....
Medicine Products: